Cash and cash equivalents of €5.7 million as of September 30, 2024Execution of clinical strategy as planned, with the GLORIA global Phase II study initiation expected in the first quarter of 2025 Lyon ...

I'd like to begin with commending our operations staff for the production levels we achieved both during the 2024 third quarter and for the nine months ended September 30, 2024. For two consecutive ...